About Prime Medicine, Inc.
https://www.primemedicine.comPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology.
CEO
Jeremy S. Duffield
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 99
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Chardan Capital
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Citigroup
Neutral
HC Wainwright & Co.
Neutral
JP Morgan
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
ALPHABET INC.
Shares:16.56M
Value:$71.38M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:9.22M
Value:$39.73M
BLACKROCK, INC.
Shares:5.65M
Value:$24.36M
Summary
Showing Top 3 of 171
About Prime Medicine, Inc.
https://www.primemedicine.comPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.23M ▲ | $11.21M ▼ | $-50.58M ▲ | -4.13K% ▲ | $-0.32 ▲ | $-48.7M ▲ |
| Q2-2025 | $1.11M ▼ | $52.63M ▼ | $-52.59M ▼ | -4.72K% ▼ | $-0.41 ▼ | $-51.51M ▼ |
| Q1-2025 | $1.45M ▼ | $53.85M ▲ | $-51.89M ▼ | -3.57K% ▼ | $-0.4 ▼ | $-50.69M ▼ |
| Q4-2024 | $2.18M ▲ | $46.41M ▼ | $-42.28M ▲ | -1.94K% ▲ | $-0.36 ▲ | $-42.51M ▲ |
| Q3-2024 | $209K | $54.44M | $-52.52M | -25.13K% | $-0.44 | $-52.67M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $208.43M ▲ | $385.01M ▲ | $223.19M ▲ | $161.82M ▲ |
| Q2-2025 | $101.75M ▼ | $279.01M ▼ | $218.15M ▼ | $60.86M ▼ |
| Q1-2025 | $144.26M ▼ | $328.16M ▲ | $221.24M ▲ | $106.92M ▼ |
| Q4-2024 | $190.44M ▲ | $297.51M ▼ | $144.36M ▲ | $153.15M ▼ |
| Q3-2024 | $175.53M | $332.78M | $143.28M | $189.5M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-50.58M ▲ | $-35.04M ▲ | $-92.12M ▼ | $144.75M ▲ | $17.59M ▲ | $-35.29M ▲ |
| Q2-2025 | $-52.59M ▼ | $-41.41M ▲ | $2.77M ▲ | $197K ▼ | $-38.44M ▲ | $-42.98M ▲ |
| Q1-2025 | $-51.89M ▼ | $-48.86M ▼ | $-47.74M ▼ | $6M ▲ | $-90.6M ▼ | $-51.28M ▼ |
| Q4-2024 | $-42.28M ▲ | $16.25M ▲ | $48.25M ▼ | $1K ▼ | $64.5M ▲ | $14.45M ▲ |
| Q3-2024 | $-52.52M | $-25.91M | $50.34M | $38.51M | $62.94M | $-27.19M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Reportable Segment | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Jeremy S. Duffield
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 99
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Chardan Capital
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Citigroup
Neutral
HC Wainwright & Co.
Neutral
JP Morgan
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
ALPHABET INC.
Shares:16.56M
Value:$71.38M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:9.22M
Value:$39.73M
BLACKROCK, INC.
Shares:5.65M
Value:$24.36M
Summary
Showing Top 3 of 171